Trulieve Cannabis Announces Uplist to NYSE
Trulieve Cannabis' (TRUL.CN) subordinate voting shares have been approved for listing on the New York Stock Exchange (NYSE), the company said on Friday.The subordinate voting shares are expected to begin trading on the NYSE under the symbol "TRLV" at the opening of trading on June 10, 2026.The company anticipates the subordinate voting shares will continue trading on the Canadian Securities Exchange under the symbol "TRUL" and the OTCQX under the symbol "TCNNF" until the close of market on June 9, 2026."Acting Attorney General Todd Blanche reclassified medical marijuana to Schedule III in April 2026, following an Executive Order by President Trump in December 2025," said the company. "The final order issued in April rescheduled state licensed medical marijuana products and created a pathway for Drug Enforcement Administration ("DEA") registration for state licensed medical marijuana businesses under the treaty authority pursuant to the United Nations Single Convention on Narcotic Drugs."Following medical marijuana rescheduling, the company completed a corporate restructuring and investment by a third party resulting in the deconsolidation of operations in markets serving both medical and adult use customers, the company said.The company's remaining consolidated operations consist only of state licensed medical marijuana facilities and include 206 medical marijuana dispensaries supported by 3.5 million square feet of production capacity registered with the DEA, it added."As the first U.S. cannabis company to list on a major U.S. exchange, we are excited for the opportunity to expand our shareholder base, increase liquidity, and raise awareness for the benefits of medical marijuana," said Kim Rivers, Founder and Chief Executive Officer of Trulieve. "Common sense action by President Trump to reclassify medical marijuana to Schedule III paved the way for this historic milestone. Uplisting to the NYSE is a major advancement for Trulieve and the industry."